Personalised Dosing of Natalizumab in Multiple Sclerosis (The PDNMS trial)
Towards personalized dosing of natalizumab in multiple sclerosis
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
Our primary endpoint is the number of patients with the formation of new Gd+ enhancing lesions on brain MRI
MRI lesions
Other measures (1)
Secondary outcome measures are the cumulative number of new/and or enlarging T2-weighted lesions on the brain MRI, clinical disease activity (number of relapses and 12-weeks sustained EDSS progression) and SF-36.
Disability progressionRelapsesMRI lesionsQuality of life (reported by participants)
Loading reviews and guidelines…
Related trials
- Natalizumab and Chronic Inflammation
Phase 4 · Stopped early
Stopped early
- Analysis of MS Patients Who Have Had Greater Than 60 Infu…
Status unknown
No result found
- TOPIK Study: A Study to Report Progressive Multifocal Leu…
Completed
No result found
- Tysabri Observational Cohort Study - Multiple Sclerosis (…
Completed
No result found
- Safety and Efficacy in Pediatric MS Patients Prescribed T…
Completed
No result found
- Does targeting of S1P receptors reduce microglial activat…
Phase 4 · Completed
No result found
History
- In scope changed from true to false
Started
Apr 2016
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error